Voyager Therapeutics, Inc. (VYGR): Revenue
$40.37M
Year ended 2025-12-31
$34.46M
Trailing 12 months to 2026-06-30
-0.4%
3-year compound annual growth
-25.1%
5-year compound annual growth
+8.8%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $40.37M | -49.5% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $80.00M | -68.0% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $250.01M | +511.2% | 2026-03-09, From 2023-01-01 |
| 2022-12-31 | $40.91M | +9.3% | 2025-03-11, From 2022-01-01 |
| 2021-12-31 | $37.41M | -78.1% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $171.13M | +63.9% | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | $104.39M | n/m | 2022-03-08, From 2019-01-01 |
| 2018-12-31 | $7.62M | -24.8% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $10.13M | -28.7% | 2020-03-03, From 2017-01-01 |
| 2016-12-31 | $14.22M | -18.0% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $17.33M | n/a | 2018-03-14, From 2015-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $40.37M | -49.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $40.52M | +25.4% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $39.55M | -31.6% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $39.21M | -16.7% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $44.64M | -6.1% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $35.95M | +1.0% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $35.11M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $34.26M | -50.1% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $52.74M | -1.2% |
Compare VYGR, EDIT, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗